Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.

Journal of medicinal chemistry - 25 Oct 2018

Ma Tianfang, Zou Fangxia, Pusch Stefan, Xu Yungen, von Deimling Andreas, Zha Xiaoming

Abstract excerpt

Isocitrate dehydrogenases 1 and 2 (IDH1/2) are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle. However, mutant IDH1/2 (mIDH1/2) reduces α-KG to the oncometabolite 2-hydroxyglutarate (2-HG). High levels of 2-HG competitively inhibit the α-KG-dependent dioxygenases involved in histone and DNA demethylation, thereby impairing normal cellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IDH1 gene

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 29847930
DOI: 10.1021/acs.jmedchem.8b00159

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.PMID 29847930Read ↗

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human CancerSemantic proximity Read ↗

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.Semantic proximity Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerSemantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.Semantic proximity Read ↗

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.